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E-mail address: sidhua@georgetown.edu (A. SidhuAlthough well-studied in the context of neurodegenerative disease, a clear biological function for
the synuclein proteins remains elusive. Emerging data indicate a role for synucleins in monoamine
neurotransmitter homeostasis. A key regulatory component of monoamine neurotransmission is
re-uptake of neurotransmitter by the dopamine transporter, norepinephrine transporter, and sero-
tonin transporter, which are common drug targets in the treatment of depression and other mood
disorders. Through interactions with these transporters, the neuronal cytoskeleton, and pre-synap-
tic scaffolding proteins, a-synuclein, b-synuclein, and c-synuclein modulate trafﬁcking, expression
and function of monoamine transporters at the cell surface, thus playing a central role in regulating
monoamine re-uptake.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The synuclein family of proteins, and especially a-synuclein
(a-Syn), has been linked to Parkinson’s disease (PD), Alzheimer’s
disease (AD), and other neurodegenerative conditions. Studied pri-
marily in this context, the synucleins continue to elude functional
classiﬁcation [1]. Emerging among competing hypotheses regarding
their function is evidence of a role for synucleins in regulating
homeostasis of the monoamine neurotransmitters dopamine (DA),
norepinephrine (NE), and serotonin (5-hydroxytryptamine, 5-HT)
[2–4]. Monoamine neurotransmission modulates many physiologi-
cal processes and is regulated, in part, by presynaptic plasma
membrane monoamine transporters (MAT), the transmembrane
proteins solely responsible for re-uptake of synaptic DA, NE, and
5-HT [5]. Due to their essential role within the brain of recovering
monoamine neurotransmitters, the MAT are important pharmaco-
logical targets in the treatment of several neuropsychiatric condi-
tions, including depression, other mood disorders, and addiction
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).indicate an important role for the synucleins in regulating trans-
porter function, trafﬁcking and distribution at the synapse. Further
elucidation of these mechanisms will bridge gaps in our knowledge
of the function of synuclein proteins in both normal and disease
states. Thus, this review is constructed with three principal goals:
(1) to summarize the characterization of synuclein proteins within
the process ofmonoamine synthesis and release; (2) to present data
that points to an interactive involvement of synucleins and MAT in
the regulation of monoamine reuptake; and (3) to outline future
directions for research into this novel mechanism of synuclein-
dependent monoamine homeostasis.
2. Synucleins in monoamine neurotransmitter release
and synthesis
Orthologous genes cloned from multiple species demonstrate
that synucleins, a group of prevalent pre-synaptic proteins, are
highly conservedbutunique to vertebrate organisms [1]. This family
of genes has been expanded to include multiple paralogues identi-
ﬁed as a-Syn, b-synuclein (b-Syn), and c-synuclein (c-Syn). Expres-
sion of these proteins varies throughout the central nervous system
(CNS) and also developmentally [1]. a-Syn, b-Syn, and c-Syn share
signiﬁcant sequence identity: an N-terminal series of 11-residue
repeats (7–87 in a-Syn), a centrally located hydrophobic region
(61–95 in a-Syn), and an acidic C-terminal domain (96–140 in
a-Syn). The central region of a-Syn composes the non-Ab compo-
nent of AD amyloid (NAC), and as such is known as the NAC domain
[1]. Synucleins participate in numerous interactions with other
proteins, lipid membranes, and nucleic acids, suggesting a possible
role in the chaperoning or trafﬁcking of biomolecules [1]. Indeed,lsevier B.V. All rights reserved.
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proteins [6], and is the most conserved region among a-Syn, b-Syn,
and c-Syn, all ofwhich possess chaperone-like activity [7]. Although
studies from single, double, and triple synuclein knockout (KO)mice
indicate that synucleins are not essential for viable development
[8–10], data from these samemice have nonetheless shown repeat-
edly that the synucleins are required for normal presynaptic
function [8–15].
Among possible presynaptic functions that synucleins may
perform is regulation of the synthesis, release, and reuptake of
monoamine neurotransmitters (Fig. 1). The involvement of synucle-
ins in monoamine homeostasis has been explored in part to deter-
mine the connection between a-Syn and the profound loss of
dopaminergic neurons that occurs in PD.a-Syn accumulates in Lewy
bodies, a hallmark of PD, and is linked with both familial and idio-
pathic forms of the disease. Availability of DA depends in part on
the activity of tyrosine hydroxylase (TH), an enzyme in the biosyn-
thetic pathways of both DA and NE (Fig. 1(1)). It was shown that
TH enzymatic activity can be regulated through direct interactions
with a-Syn [16], and that expression of THwas increased in the ret-
ina of a-Syn/c-Syn double knockout (KO) mice compared to wild
type and single KOmice [14]. While no evidence exists for an inter-
action between b-Syn and TH, it has been suggested that b-Syn over-
laps functionally with a-Syn [1]. No reports have emerged of a
similar interaction between synucleins and tryptophanhydroxylase
(TrH), the rate-limiting enzyme in the production of 5-HT. Loss of
TrH neurons in serotonergic nuclei, however, has also been associ-
ated with neurodegenerative synucleinopathies [17].
In addition to regulation of neurotransmitter synthesis, synu-
cleins are involved in the storage of neurotransmitters (Fig. 1(2)).
Release of synthesized neurotransmitter by monoaminergic neu-
rons in the brain requires packaging of DA, NE, or 5-HT into vesicles
by the vesicular monoamine transporter 2 (VMAT2). VMAT2 co-Fig. 1. Synucleins modulate monoamine homeostasis. Monoamine neurotransmit-
ter signaling in the brain is regulated at several levels, including biosynthesis (1),
vesicular reﬁlling and release (2–4), and reuptake (5). All of these processes are
impacted by at least one member of the synuclein family of proteins. The activity of
tyrosine hydroxylase, which is on the biosynthetic pathway (1) of dopamine and
norepinephrine, is modulated by a-Syn [16]. Synthesized monoamine neurotrans-
mitters must be loaded into vesicles through the vesicular monoamine transporter
(VMAT2). Expression and activity of VMAT2 can be modulated by a-Syn [1,18], thus
regulating the rate of vesicular reﬁlling (2). Synuclein levels alter the number and
distribution of neurotransmitter vesicles [8,9,11,13,15], thus directly impacting the
process of vesicle translocation (3). SNARE-mediated fusion of vesicles with pre-
synaptic membrane releases monoamine neurotransmitters into the synapse (4).
Formation of functional SNARE complexes is dependent on normal synuclein levels
[10]. Finally, released neurotransmitter is cleared from the synapse by the
monoamine transporters (MAT). MAT function is dependent on regulated trafﬁck-
ing to the cell surface (5), which is modulated by all three synucleins [3,4,23,24,27–
39,46].localizes with a-Syn in the Lewy bodies of PD [18], and overexpres-
sion of a-Syn can disrupt VMAT2 function in various contexts [1].
The inﬂuence of b-Syn and c-Syn upon VMAT2 expression and
activity are not known.
Synaptic vesicles ﬁlled by VMAT2 must be translocated prior to
neurotransmitter release, and are subject to regulated trafﬁcking to
the cell surface (Fig. 1(3)). Maintenance of normal levels of the
monoamine neurotransmitters is in part dependent on the num-
ber, size, and location of loaded vesicles. a-Syn KO mice have re-
duced DA and NE storage capacity, and ultrastructural studies
show a depleted reserve pool of monoamine storage vesicles
[11,13,15]. Dopaminergic and noradrenergic activity in these ani-
mals may be preserved through an increased rate of vesicular
reﬁlling, suggesting a compensatory mechanism that produces an
outwardly normal phenotype, even in the absence of a-Syn expres-
sion [13,15]. Double a-Syn/b-Syn KO mice have synaptic ultra-
structure similar to single KO mice, and striatal DA content in
these animals is signiﬁcantly reduced compared to single KO mice
[9]. Studies on double a-Syn/c-Syn KO mice did not reveal altered
DA content [12], though a hyperdopaminergic phenotype supports
the conclusion that the absence of synucleins alters the manage-
ment of monoamines in presynaptic vesicle pools [8].
Release of neurotransmitters, including DA, NE, and 5-HT, re-
quires fusion of loaded vesicles with the presynaptic membrane
through a soluble N-ethylmaleimide-sensitive factor attachment
protein receptor (SNARE) dependent process [19]. SNARE-depen-
dent vesicle activity occurs on a millisecond time scale, and is
tightly regulated by other pre-synaptic proteins, including the
co-chaperone cysteine-string protein a (CSPa) [19]. Deletion of
CSPa produces a lethal neurodegenerative phenotype that is re-
versed by over-expression of a-Syn, restoring normal levels of
SNARE complex assembly [19]. a-Syn interacts with the SNARE
protein SNAP-25, and promotes SNARE assembly in vitro [10], sug-
gesting that synucleins participate in the process of neurotransmit-
ter release through an interaction with the vesicle exocytosis
machinery (Fig. 1(4)). Indeed, triple a-Syn/b-Syn/c-Syn KO mice,
though viable, develop deﬁcits in motor function and show im-
paired SNARE complex assembly in the brain [10]. This result indi-
cates a direct and functionally consequential involvement of
synucleins in SNARE-dependent presynaptic activity. While a key
function of SNARE proteins is regulation of neurotransmitter re-
lease, the SNARE complex is also activated in other processes that
require trafﬁcking of vesicles or other membrane-bound structures
to the presynaptic membrane, including the process of neurotrans-
mitter reuptake that is performed by the dopamine transporter
(DAT), norepinephrine transporter (NET), and serotonin trans-
porter (SERT).3. Synuclein modulation of MAT
DAT, NET, and SERT have highly similar primary sequences of
620, 617, and 630 amino acids, respectively [5]. They share 12 pre-
dicted a-helical transmembrane domains, and each transporter
has extended intracellular tails as well as large extracellular loops
that are subject to numerous post-translation modiﬁcations and
may be involved in MAT regulation [5]. Localized to the plasma
membrane of pre-synaptic neurons, MAT have a central role in
monoamine homeostasis, providing the primary means by which
their respective neurotransmitter substrates can be removed from
the synapse (Fig. 1(5)) [5]. This reuptake action regulates neuro-
transmission by terminating signaling as DA, NE, or 5-HT are
drawn back into the presynaptic neuron. Reuptake also serves as
a ﬁrst step in neurotransmitter recycling, placing recovered mono-
amines in position for reloading into synaptic vesicles [5]. MAT
trafﬁcking and activity at the cell surface is regulated by the SNARE
Fig. 2. Synuclein modulation of monoamine transporter trafﬁcking. Monoamine
transporters (MAT) are synthesized and transported to the pre-synaptic membrane
on membrane-bound structures. Before arriving at the cell surface, MAT must travel
along the axon via a microtubule network (1), transit the actin microﬁlament
matrix (2), and fuse with the cell surface in a SNARE-dependent manner (3). These
processes are each impacted by some or all of the synuclein proteins. a-Syn is
involved in mediating microtubule-based MAT transport (1), as modulation of both
DAT and NET by a-Syn is dependent upon an intact microtubule cytoskeleton
[24,27–29]. a-Syn also mediates actin-based MAT transport (2), as modulation of
NET by a-Syn is dependent on an intact actin cytoskeleton [27]. Synucleins enable
normal SNARE complex formation [10], suggesting that SNARE-dependent insertion
of MAT into the plasma membrane is also modulated by synucleins (3). Modulation
of MAT by b-Syn and c-Syn is not sensitive to agents that target the cytoskeleton
[24], and may occur through a distinct, as yet un-identiﬁed mechanism (4).
Table 1
Characterization of synuclein–MAT interactions. Physical interactions determined by
yeast two-hybrid screens or co-immunoprecipitation. Modulation of surface expres-
sion determined by neurotransmitter uptake assays, behavioral response to cocaine,
cell fractionation, and biotinylation experiments. Microtubule and actin dependence
of modulation determined in the presence of cytoskeleton disrupting agents. +,
occurs; –, no effect/does not occur; ", increase; ;, decrease; "/;, concentration
dependent; ND, not determined; N/A, not applicable. References are as noted.
DAT NET SERT References
Physical interaction with
a-Synuclein + + + DAT: [23,26,29–33]
NET: [3,24,27,28]
SERT: [4,46]
b-Synuclein ND ND – SERT: [46]
c-Synuclein ND + + NET: [24]
SERT: [46]
Modulation of surface expression
a-Synuclein "/; "/; ; DAT: [23,29–38]
NET: [3,24,27,28]
SERT: [29,46]
b-Synuclein ND ; – NET: [24]
SERT: [46]
c-Synuclein ; ; ; DAT: [39]
NET: [24]
SERT: [46]
Modulation is microtubule dependent
a-Synuclein + + ND DAT: [29]
NET: [24,27,28]
b-Synuclein ND – N/A NET: [24]
c-Synuclein ND – ND NET: [24]
Modulation is actin dependent
a-Synuclein ND + ND NET: [27]
b-Synuclein ND ND N/A N/A
c-Synuclein ND ND ND N/A
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is in part dependent on the synucleins [10], it is possible that synu-
cleins also play a role in mediating the effects on MAT of Synt-1
(Fig. 2(3)), although this has not been directly demonstrated.
In addition to putative modulation of MAT function through ef-
fects on SNARE proteins, synucleins appear to directly regulate
MAT by another, possibly independent, mechanism (Fig. 2). Synu-
cleins were identiﬁed as potential participants in MAT regulatory
processes due to their overlap in localization and mutual involve-
ment in diseases of the monoaminergic systems [23]. Through pro-
tein:protein interactions with DAT, NET, and SERT, it has been
shown that a-Syn, b-Syn, and c-Syn can each modulate trafﬁcking
of some or all of these transporters to the cell surface, thus inﬂu-
encing reuptake of neurotransmitters [2,4,24]. Trafﬁcking of MAT
is dependent upon interactions with the cytoskeleton and other
pre-synaptic scaffolding proteins [25,26], and these interactions
between MAT and the cytoskeleton can be modulated by the synu-
cleins (Fig. 2(1) and (2)) [24,27–29]. Regulation of MAT function by
different mechanisms can be variously positive (increases uptake)
or negative (decreases uptake), and there is evidence that synucle-
ins can inﬂuence MAT trafﬁcking both positively and negatively
[23,27]. Data in support of an important role for a-Syn, b-Syn,
and c-Syn in modulation of DAT, NET, and SERT continues to accu-
mulate (Table 1), and will be described in detail below.
4. Synuclein modulation of DAT
The most thoroughly investigated synuclein-MAT interaction is
that between a-Syn and DAT. Initial yeast two-hybrid and immu-
noprecipitation experiments identiﬁed a physical interaction be-
tween a-Syn and the carboxy terminal of DAT [23]. Afﬁnity
puriﬁcation experiments showed that the NAC domain of a-Syn
mediates the interaction with DAT [30]. Though little doubt re-
mains as to the existence of a physical interaction between a-
Syn and DAT, results characterizing the functional signiﬁcance of
this interaction are conﬂicting, showing that overexpression of a-
Syn in DAT expressing cells can variously increase or decrease
DAT trafﬁcking to the cell surface under different conditions
[23,31]. It was proposed that a-Syn overexpression enhanced neu-rodegenerative processes by promoting the inﬂux of DA, a com-
pound which in excess becomes cytotoxic through the induction
of oxidative damage [23]. These results prompted further study,
which uncovered inconsistencies in the observed phenomena.
Ourworkhas established a large body of evidencedemonstrating
negative modulation of DAT by a-Syn. While a physical interaction
betweena-SynandDATwas conﬁrmedby co-immunoprecipitation,
the positive inﬂuence of a-Syn on DAT trafﬁcking has not been
reconﬁrmed. Experiments in several cell lines as well as cultured
rat neurons showed dose-dependent reduction of cell surface DAT
expressionbya-Syn [29–33]. Together, the data indicates thatwhen
co-expressed with DAT, the role of a-Syn is to reduce DAT function
by limiting cell surface expression through increased trafﬁcking
away from the cell surface. This interaction does not appear to alter
the function of the transporter, as afﬁnity for substrate was
unaffected. Rather, DAT availability is reduced, as indicated by the
reduction of maximum uptake capacity observed in co-transfected
cells [30].
Studies using lentiviral vectors to modify endogenous levels of
a-Syn in the rat brain show that the locomotor response to cocaine
is also a-Syn dependent [34]. Hyperlocomotion following adminis-
tration of cocaine is thought to result from blockade of DAT, the ef-
fect of which is to prevent clearance of DA from the synapse.
Extended DA signaling then causes abnormally high measures on
a standard behavioral measure of locomotor activity, such as total
distance traveled. Increases in a-Syn levels are associated with in-
creases in the locomotor response, suggesting that a-Syn retards
cell-surface localization of DAT. That is, with high levels of a-Syn,
less DAT is available at the cell surface, and the cocaine blockade
of DA transport is longer and more complete than it would be un-
der normal conditions, producing the observed increase in the
locomotor response [34]. These results are consistent with a model
wherein DAT is negatively modulated by increases in endogenous
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DAT is a homeostatic process that is extremely context dependent.
The effects of a-Syn on DAT can be modulated by the adherent
properties of co-expressing cells, the route of administration of
a-Syn, or the means of regulation of a-Syn expression [32,35–
37]. Data have shown that knockdown or overexpression of a-
Syn can have unexpected effects on DAT, and may impact other as-
pects of DAT function, including synthesis and export from the Gol-
gi apparatus [38]. Further assessment of the interaction between
the endogenous regulatory processes controlling a-Syn expression
and DAT activity is required to resolve the complex functional
relationship between these proteins.
Given the overall sequence similarity of a-Syn and c-Syn, and
greater than 50% identity in the NAC domain, it was a logical
progression to look for a similar interaction between c-Syn and
DAT. Indeed, knock-down of endogenous c-Syn expression with
lentiviral siRNA also signiﬁcantly reduces the locomotor response
to cocaine, while overexpression of c-Syn and DAT resulted in
increased locomotor activity [39]. Further investigation into this
phenomenon is required, as the mechanism by which c-Syn mod-
ulates DAT has not been addressed. Nonetheless, the ﬁnding that
c-Syn and a-Syn modulate DAT in a similar manner provides con-
ﬁrmation of the importance of the NAC domain in mediating MAT
modulation synucleins. As predicted by this line of reasoning, no
interaction has thus far been identiﬁed between b-Syn and DAT.
Another feature of synuclein–DAT interactions is the depen-
dence of a-Syn modulation of DAT on an intact microtubule cyto-
skeleton. Nocodazole, a microtuble destabilizing agent, reverses
the a-Syn dependent inhibition of DAT [29], indicating that the ob-
served modulation of DAT by a-Syn requires a cytoskeletal sub-
strate on which to anchor the transporter. The dependence of
synuclein modulation of MAT on the cytoskeleton is discussed in
greater detail below.5. Synuclein modulation of NET
Noradrenergic projections are present throughout the CNS and
the regulation of their NE release is tied to NET expression and cell
surface localization. The nature of the interactions between synuc-
lein proteins and NET is established by a small number of studies.
Given the similarities in structure and function between the MAT,
however, it is not surprising that a similar set of results emerged
from cellular models of NET trafﬁcking. An increasing level of a-
Syn expression negatively modulates NET uptake activity by
decreasing NET expression at the cell surface [3,28]. Physical inter-
action between a-Syn and NET was conﬁrmed by co-immunopre-
cipitation from both cultured cells and rat brain tissue, and it
was shown that the observed physical and functional interaction
was dependent on the NAC domain [3].
Modulation of NET by a-Syn is not strictly monotonic, as
different ratios of co-transfection are capable of producing either
positive or negative effects on NET trafﬁcking [28]. Low levels of
a-Syn (0.5:1 co-transfection ratio) induce an increase in NET up-
take capacity compared to a-Syn negative cells, while overexpres-
sion (3:1 co-transfection ratio) brings about a decrease in the Vmax
of NE uptake [28], without altering afﬁnity for the NE substrate.
Cell surface expression and physical interaction (co-immunopre-
cipitation of NET and a-Syn) follows a similar pattern. This ﬁnding
supports a homeostatic role for synucleins, indicating that normal
NET expression may depend upon a certain baseline level of synuc-
lein–NET interaction, and that extremes of expression both above
and below this level can result in negative modulation of NET
activity. While this pattern of regulation has not been demon-
strated within any single study on DAT (see above), what appear
to be conﬂicting observations from separate studies may in factbe demonstrating the functional effects of expression either above
or below the level for ‘‘optimal’’ synuclein–DAT interaction.
NET trafﬁcking is also modulated by both b-Syn and c-Syn, as
increased expression of either synuclein reduces cell-surface NET
in vitro [24]. Modulation of NET by b-Syn is surprising in that it
must be NAC-domain independent, as this domain is almost en-
tirely absent in the b-Syn protein. Though the effects of b-Syn
and c-Syn in co-transfected cells are monotonic, experiments on
Wistar (WIS) and Wistar-Kyoto (WKY) rats have revealed a com-
plex three-way interaction between a-Syn, c-Syn, and NET expres-
sion [24], suggesting that multiple synuclein binding partners of
NET may cooperate or compete presynaptically to accomplish
transporter modulation.
WKY rats are an outbred strain of WIS rats, and have a depres-
sive-like phenotype that is well characterized on traditional behav-
ioral measures such as the forced swim test [40]. These animals
have reduced expression of NET, which also occurs in patients with
major depression [24,41]. Reduced expression of NET may be part
of a homeostatic mechanism that attempts to compensate for re-
duced NE release in major depression [42]. NET is the target of
many antidepressant drugs, the acute effect of which is to further
limit re-uptake of synaptic NE. Chronic exposure to antidepres-
sants also alters cell-surface levels of NET, reducing availability
of the transporter in the brain [43]. Given that NET trafﬁcking is
modulated by a-Syn, b-Syn, and c-Syn, it was hypothesized that
synuclein expression and NET trafﬁcking in the WKY strain would
differ from the WIS control strain [24]. Furthermore, it was pro-
posed on the basis of the available information on antidepressant
effects on NET function and expression, that chronic treatment
with the tri-cyclic antidepressant desipramine (DMI) would im-
prove depressive-like behavior, possibly by a mechanism involving
alterations in the expression, distribution, and interactions of syn-
uclein proteins [24].
The ﬁndings were consistent with previous observations on the
mechanisms underlying depression and antidepressant therapy in
the human population. WKY rats displayed a more depressive-like
behavioral phenotype and had lower overall NET expression, both
of which were altered by chronic administration of DMI [24]. Dif-
ferences in the baseline expression levels of a-Syn to c-Syn were
also detected between these animals. More importantly, chronic
DMI treatment induced a shift in both the balance and the distribu-
tion of a-Syn and c-Syn expression throughout the brain [24,41].
These changes in synuclein expression are associated with altered
interactions with NET and the microtubule cytoskeleton [24]. It
was not determined whether these shifts in expression were asso-
ciated with alterations in synuclein transcription, and future work
should address this question directly. Transcriptional regulation of
synuclein mRNA expression is poorly understood, and the identiﬁ-
cation of a mode of regulation that responds to drug treatment
could be an important means for addressing the broad range of
mood and neurodegenerative conditions potentially impacted by
synuclein imbalances.
Thea-Syn-dependentmodulation of NET cell-surface expression
was reversed by treatment with the microtubule destabilizing
agents nocodazole, colchicine, and vinblastine [27,28]. An intact, dy-
namic actin cytoskeleton was also required for the a-Syn modula-
tion of NET to occur [27]. Modulation of NET by b-Syn and c-Syn,
however, was not affected by treatment of co-transfected cells with
nocodazole [24]. In the rat brain, the effect of nocodazole on NE up-
take was dependent on the relative expression of a-Syn and c-Syn.
In synaptosomes isolated from tissues where a-Syn is the predomi-
nant synuclein, NET activity is nocodazole sensitive [24]. Increased
expression of c-Syn, however, disconnects NET modulation from
the integrity of the microtubule cytoskeleton. Distribution of
c-Syn in cultured cells was not altered bymicrotubule destabilizers
[44], and that the efﬁcacy of microtubule-directed chemotherapeu-
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with a depressive-like phenotype, chronic administration of the
NET-selective antidepressant (DMI) decreased c-Syn expression
and increased the sensitivity of NET distribution to nocodazole
[24]. Taken together, theseﬁndings suggest thatc-Syn is responsible
for cytoskeleton-independent regulation of diverse cellular pro-
cesses, including noradrenergic neurotransmission. b-Syn modula-
tion of NET in co-transfected cells is also resistant to nocodazole
[24], indicating that b-Syn may also act on NET in a microtubule
independent manner, though more studies will be required to ade-
quately describe this process.
6. Synuclein modulation of SERT
Physical and functional interactions between synuclein proteins
and SERT have also been assessed, showing that the impact of a-Syn
overexpression on SERT trafﬁcking follows the general pattern ob-
servedwith DAT and NET. Cell-surface expression and uptake activ-
ity of SERT in co-transfected cells arenegativelymodulatedbya-Syn
in anNAC-domain dependentmanner [4]. A physical interaction be-
tweena-Syn and SERTwas conﬁrmed by immunoprecipitation both
in cultured cells and in rat brain tissue [4], and interactions between
SERT andc-Synhave beendemonstrated in co-transfected cells [46].
An assessment of c-Syn and b-Syn interactions shows that while
b-Syn does not modulate SERT activity, overexpression of c-Syn
can induce partial negative modulation of SERT distribution to the
cell surface [46]. It is not yet clear whether modulation of SERT traf-
ﬁcking by the synucleins is dependent on the microtubule or actin
cytoskeletons. Preliminary ﬁndings indicted that microtubule
destabilizing agents disrupt a-Syn modulation of SERT, reversing
the inhibition of uptake in co-transfected cells [A. Sidhu, unpub-
lished data]. Also, rat brain synaptosomes have a microtubule-
dependent component of SERT uptake capacity that can be accessed
by treatment with nocodazole, which may therefore be modulated
by the relative levels of a-Syn and c-Syn expression [A. Sidhu,
unpublished data].7. Synuclein and MAT at the synapse
A key feature of all a-Syn–MAT interactions has been their
requirement of the NAC domain, which is well-conserved between
a-Syn and c-Syn. Though this dependence has not been demon-
strated clearly for c-Syn modulation of MAT, both synucleins that
contain the NAC domain are found in complex with MAT. While
b-Syn, which is missing most of this sequence, can modulate NET
when overexpressed [24], it does not modulate SERT, nor has a
physical interaction with any MAT yet been demonstrated. One
possible conclusion that emerges is that the NAC domain is not
only necessary for interaction with MAT, it is also sufﬁcient for mod-
ulation of transporter activity. Thus, synucleins, through interac-
tions of this domain with MAT, may be displacing or
cooperatively enhancing interactions with another MAT binding
partner in a manner that either blocks insertion and or promotes
endocytosis of the transporters. The trafﬁcking of MAT, and ulti-
mately the level of cell surface expression, appears to also depend
on the cytoskeletal elements of the cell. A model emerges wherein
synucleins tether MAT to the cytoskeleton (Fig. 2(1) and (2)), yet
are differentially sensitive to targeted disruption of cytoskeletal
components, enabling ﬁne-tuning of MAT trafﬁcking through di-
verse pre-synaptic protein–protein interactions (Fig. 2(3) and (4)).
8. Future studies
Investigation into the involvement of synuclein proteins in
SNARE-mediated regulation of MAT trafﬁcking and activity is war-ranted given the important contributions of this process to mono-
amine homeostasis [20–22]. Furthermore, it was recently
demonstrated that SNARE complex formation is partially depen-
dent on expression of the synuclein proteins [10], which strongly
suggests that modulation of MAT by synucleins involves interac-
tions with SNARE proteins, likely including Synt-1. A uniﬁed
description of presynaptic MAT trafﬁcking that involves both
SNARE proteins and the synucleins is an attractive theory that
would synthesize mechanisms that to this point have been de-
scribed in isolation. Progress in this area will likely require contin-
ued utilization of a-Syn/b-Syn/c-Syn triple KO animals, which are
the only synuclein KO mice to display a prominent behavioral and
neurochemical phenotype [8,10–13,15]. Indeed, studies of single
a-Syn KO mice, along with other models of synuclein function,
have produced some negative results that highlight the need for
a more nuanced approach in this area of investigation [47,48].
Nonetheless, the body of work described here deﬁnes synucleins
among the crowded presynaptic milieu as a means by which
monoamine neurotransmission can be regulated. In particular,
modulation of DAT, NET, and SERT by the synucleins stands out
as especially important because of the central role of these trans-
porters not only in normal neuronal signaling, but in a range of dis-
ease states including mood disorders and neurodegenerative
conditions.
Future work should also attempt to address the mechanisms by
which antidepressants and other MAT-directed drugs alter synuc-
lein expression. This stems from the ﬁnding that chronic treatment
with DMI induces changes in a-Syn and c-Syn expression [24,41].
Additional studies have now linked antidepressant drugs with syn-
uclein expression [49,50], and though it is not knownhow this effect
is exerted, further investigation could help elucidate the mecha-
nisms responsible for transcriptional and translational control of
synucleins. Furthermore, the mechanism by which synuclein
expression alters MAT distribution should be investigated to
determine the inﬂuences of synuclein expression on Synt-1-depen-
dent trafﬁcking ofMAT. Studies have indicated a clear role fora-Syn,
b-Syn, and c-Syn in the trafﬁcking ofMAT, and suggest that synucle-
ins are likely to affectmanyother presynaptic proteins that take part
in this complex, multi-faceted process.
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